Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...
If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback